Current Practices in the Management of Chronic Myeloid Leukemia

详细信息    查看全文

• 作者：Hagop M. Kantarjian¹ ; ^{hkantarj@mdanderson.org} ; Richard A. Larson² ; Jorge E. Corté ; s¹ ; Kathleen L. Deering³ ; Michael J. Mauro⁴
• 关键词：CML ; Guidelines ; Practice patterns ; Survey ; Tyrosine kinase inhibitors
• 刊名：Clinical Lymphoma Myeloma and Leukemia
• 出版年：2013
• 出版时间：February, 2013
• 年：2013
• 卷：13
• 期：1
• 页码：48-54
• 全文大小：458 K

文摘

Background

A previous survey of physician self-reported practice patterns in the management of CML was conducted in 2005. The National Comprehensive Cancer Network and European LeukemiaNet guidelines now include nilotinib and dasatinib in their treatment algorithms for CML. To assess these new guidelines, a cross-sectional survey of US hematologists and/or oncologists was conducted in December 2010 through an online survey.

Materials and Methods

The survey had 43 questions consisting of items updated from the 2005 survey to reflect changes in clinical practice, tyrosine kinase inhibitor therapy, and current guidelines.

Results

Analysis of the responses from 507 board certified medical oncologists/hematologists suggests that the use of imatinib 400 mg as an initial treatment option had decreased from 62 % in 2005 to 52 % in the 2010 survey. Currently, nearly 40 % of physicians would choose either nilotinib or dasatinib as first-line treatment. From the surveyed physicians, achievement of at least a major molecular response (MMR) is the predominant treatment goal in chronic phase CML.

Conclusion

This survey emphasizes the need for continued updates and education regarding optimal therapy, monitoring practices, and therapeutic end points in CML.